Data from PIK3CA Mutations in In situ and Invasive Breast Carcinomas

Authors:
  • AMAlexander Miron
    Alexander Miron
  • MVMaria Varadi
    Maria Varadi
  • DCDaniel Carrasco
    Daniel Carrasco
  • HLHailun Li
    Hailun Li
  • LLLauren Luongo
    Lauren Luongo
  • HKHee Jung Kim
    Hee Jung Kim
  • SPSo Yeon Park
    So Yeon Park
  • ECEun Yoon Cho
    Eun Yoon Cho
  • GLGretchen Lewis
    Gretchen Lewis
  • SKSarah Kehoe
    Sarah Kehoe
  • JIJ. Dirk Iglehart
    J. Dirk Iglehart
  • DDDeborah Dillon
    Deborah Dillon
Open Access
Publisher website
Google Scholar
Abstract
The PIK3 signaling pathway has been identified as one of the most important and most frequently mutated pathways in breast cancer. Somatic mutations in the catalytic subunit of PIK3CA have been found in a significant fraction of breast carcinomas, and it has been proposed that mutant PIK3CA plays a role in tumor initiation. However, the majority of primary human tumors analyzed for genetic alterations in PIK3CA have been invasive breast carcinomas and the frequency of PIK3CA mutations in preinvasive lesions has not been explored. To investigate this, we sequenced exons 9 and 20 of PIK3CA in pure ductal carcinoma in situ (DCIS), DCIS adjacent to invasive carcinoma, and invasive ductal breast carcinomas. In a subset of cases, both in situ and invasive areas were analyzed from the same tumor. We found that the frequency of PIK3CA mutations was essentially the same (∼30%) in all three histologic groups. In some cases, in situ and invasive areas of the same tumor were discordant for PIK3CA status, and in two cases in which multiple invasive and adjacent in situ areas within the same tumor were analyzed independently, we detected intratumor heterogeneity for PIK3CA mutations. Our results suggest that mutation of PIK3CA is an early event in breast cancer that is more likely to play a role in breast tumor initiation than in invasive progression, although a potential role for exon 9 mutations in the progression of a subset of DCIS cases cannot be excluded. Cancer Res; 70(14); 5674–8. ©2010 AACR.